Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial
Tóm tắt
Atrial fibrillation (AF) is the most common arrhythmia and has an increasing impact on public health because of its morbidity and mortality. Clinical and diagnostic tests to predict the recurrence of arrhythmia and clinical events before AF becomes permanent are still an open issue. 307 out of 1442 patients in sinus rhythm, at high risk of recurrence of AF enrolled in the GISSI-AF study, participated in a substudy with echocardiographic and biohumoral evaluation at baseline and at 12-month follow-up. The relations between biomarker concentrations and echocardiographic parameters with study endpoints in 1 year, were analysed by a stepwise multivariable Cox model (entry criteria p < 0.5 and stay criteria p < 0.2). The echocardiographic variables, cardiac markers and clinical variables considered in the statistical model indicated a higher concentration of NT-proBNP at baseline as the strongest factor related to time of first AF recurrence (HR 1.42; 95 %CI 1.23–1.46), first CV hospitalization (HR 1.58; 95 %CI 1.31–1.92) and increasing duration of recurrent AF (OR 2.16; 95 %CI 1.52–3.08). Valsartan treatment was not related to clinical events. In patients in sinus rhythm with a history of AF a higher concentration of NT-proBNP at baseline was the strongest independent risk factor for first AF recurrence and its duration, and for the first hospital admission for cardiovascular reasons.
Tài liệu tham khảo
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129:837–47.
Camm AJ, Lip GY, De Caterina R, et al. ESC committee for practice guidelines-CPG; document reviewers. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation--developed with the special contribution of the european heart rhythm association. Europace. 2012;14:1385–413.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/american heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014;64:e1–76.
Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation. 2012;125:1605–16.
Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (apixaban for the prevention of stroke in subjects with atrial fibrillation). J Am Coll Cardiol. 2013;61:2274–84.
Hijazi Z, Siegbahn A, Andersson U, et al. ARISTOTLE investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2014;129:625–34.
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart. 2014;100:1193–200.
Disertori M, Latini R, Barlera S, et al. The GISSI-AF investigators.Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–17. Erratum in: N Engl J Med. 2009;360:2379.
Disertori M, Lombardi F, Barlera S, et al. GISSI-AF investigators. Clinical predictors of atrial fibrillation recurrence in the gruppo italiano per lo studio della sopravvivenza nell’Infarto miocardico-atrial fibrillation (GISSI-AF) trial. Am Heart J. 2010;159:857–63.
Disertori M, Latini R, Maggioni AP, et al. GISSI-AF investigators. Rationale and design of the GISSI-atrial fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med (Hagerstown). 2006;7:29–38.
Lang RM, Bierig M, Devereux RB, et al. Chamber quantification writing group; american society of Echocardiography’s guidelines and standards committee; european association of echocardiography. Recommendations for chamber quantification: a report from the american society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the european society of cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.
Staszewsky L, Wong M, Masson S, et al. GISSI-AF investigators. Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy. Circ Cardiovasc Imaging. 2011;4:721–8.
Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, Belvito C, et al. Latini R; GISSI-AF investigators. Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. Heart. 2010;96:1909–14.
Latini R, Masson S, Pirelli S, et al. GISSI-A investigators. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. J Intern Med. 2011;269:160–71.
Letsas KP, Filippatos GS, Pappas LK, et al. Determinants of plasma NT-pro-BNP levels in patients with atria fibrillation and preserved left ventricular ejection fraction. Clin Res Cardiol. 2009;98:101–16.
Hussein AA, Saliba WI, Martin DO, et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation. 2011;123:2077–82.
Therkelsen SK, Groenning BA, Kjaer A, Svendsen JH, Boje JG. ANP and BNP in atrial fibrillation before and after cardioversion--and their relationship to cardiac volume and function. Int J Cardiol. 2008;127:396–409.
Schnabel RB, Wild PS, Wilde S, et al. Multiple biomarkers and atrial fibrillation in the general population. PLoS One. 2014;17:9e112486.
Schnabel RB, Larson MG, Yamamoto JF, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010;121:200–7.
Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–63.
Knudsen CW, Omland T, Clopton P, et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005;46:838–44.
Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–8.
Ellinor PT, Low AF, Patton KK, Shea MA, Macrae CA. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol. 2005;45:82–6.
Pikkarainen S, Tokola H, Kerkelä R, Majalahti-Palviainen T, Vuolteenaho O, Ruskoaho H. Endothelin-1-specific activation of B-type natriuretic peptide gene via p38 mitogen-activated protein kinase and nuclear ETS factors. J Biol Chem. 2003;278:3969–75.